1.15

13.86% 0.14

After Hours: 1.09 -0.06 -5.22%

Phio Pharmaceuticals Corp (PHIO)

Overview News Price History Financials Why PHIO Down? Discussions Forecast Stock Split

Phio Pharmaceuticals Corp stock is traded at $1.15, with a volume of 857.22K. It is up +13.86% in the last 24 hours and up +24.32% over the past month. Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

Previous Close:

$1.01

Open:

$1.05

24h Volume:

857.22K

Relative Volume:

0.24

Market Cap:

$12.38M

Revenue:

Net Income/Loss:

$-7.95M

P/E Ratio:

-0.5139

EPS:

-2.2377

Net Cash Flow:

$-7.28M

1W Performance:

+9.52%

1M Performance:

+24.32%

6M Performance:

-44.17%

1Y Performance:

-12.88%

1-Day Range:

$1.04

$1.15

1-Week Range:

$0.978

$1.16

52-Week Range:

$0.8127

$4.1899

Phio Pharmaceuticals Corp Stock (PHIO) Company Profile

Name

Phio Pharmaceuticals Corp

Sector

Healthcare (1106)

Industry

Biotechnology (620)

Phone

(508) 767-3861

Address

411 SWEDELAND ROAD, KING OF PRUSSIA, MA

Employee

Twitter

@phio_pharma

Next Earnings Date

2024-11-07

Latest SEC Filings

PHIO's Discussions on Twitter

Compare PHIO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PHIO Phio Pharmaceuticals Corp	1.15	10.87M	0	-7.95M	-7.28M	-2.2377
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-05-25	Resumed	H.C. Wainwright	Buy
Aug-05-20	Initiated	H.C. Wainwright	Buy

Phio Pharmaceuticals Corp Stock (PHIO) Latest News

06:18 AM

PHIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

06:18 AM

Mar 03, 2026

Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients - Sahm

Mar 03, 2026

Feb 25, 2026

PHIO Should I Buy - Intellectia AI

Feb 25, 2026

PHIO Technical Analysis & Stock Price Forecast - Intellectia AI

Feb 25, 2026

Feb 23, 2026

Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company - Weekly Voice

Feb 23, 2026

Phio Pharmaceuticals Reports Promising Phase 1b Results for Skin Cancer Therapy, Plans FDA Submission for 2026 - citybuzz -

Feb 23, 2026

Feb 21, 2026

Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894 - The Courier-Journal

Feb 21, 2026

Feb 20, 2026

Is Phio Pharmaceuticals Corp. stock trending bullish2025 Major Catalysts & Advanced Technical Analysis Signals - mfd.ru

Feb 20, 2026

Feb 19, 2026

CVI and Heights disclose 9.9% Phio (PHIO) stake based on warrant holdings - Stock Titan

Feb 17, 2026

Feb 16, 2026

Will Phio Pharmaceuticals Corp. benefit from rising consumer demandWeekly Investment Report & Advanced Swing Trade Entry Alerts - mfd.ru

Feb 16, 2026

Feb 15, 2026

What are Phio Pharmaceuticals Corp.’s growth leversInsider Buying & AI Forecast for Swing Trade Picks - mfd.ru

Feb 15, 2026

DealFlow Discovery Conference: Opportunities Unveiled - timothysykes.com

Feb 15, 2026

Feb 14, 2026

Can Phio Pharmaceuticals Corp. lead its sector in growthEarnings Growth Summary & Growth Focused Stock Reports - mfd.ru

Feb 14, 2026

Feb 13, 2026